摘要
目的探讨黄嘌呤氧化还原酶(XOR)在非小细胞肺癌患者中的表达情况,并探讨其对患者预后的影响。方法采用免疫组织化学技术,检测120例非小细胞肺癌患者术后切除标本的XOR表达情况,并分析其与预后之间的关系。结果癌旁组织未表达XOR,肺癌组织XOR阳性表达率为44.2%,在不同病理类型肺癌间表达差异无统计学意义。XOR表达与淋巴结转移和TNM分期间存在密切关系。XOR阳性表达患者5年生存率为11.3%,阴性表达者为38.8%,两者差异具有统计学意义。结论 XOR可以作为评价非小细胞肺癌预后的重要参考依据。
Objective To investigate the expression of xanthine oxidoreductase （XOR） and its prognostic value in patients with non- small cell lung cancer （NSCLC）. Methods Immunohistochemical staining was performed on the dissected specimen from 120 patients with NSCLC. The prognostic value of the XOR immunostaining was evaluated. Results Positive XOR expression was observed in 44.2% of cases, while a negative XOR expression was observed in all the normal tissues. There was no significant difference in different pathological cancer. The expression of XOR was related to tumor TNM stage and lymph node metastasis. The cumulative 5-years survival rate in patients with positive XOR expression was 11.3%, compared with 38.8% in those with negative expression. Conclusion Expression of XOR may be a new prog- nostic marker for patients with NSCLC.
出处
《安徽医学》
2013年第3期266-268,共3页
Anhui Medical Journal
关键词
非小细胞肺癌
黄嘌呤氧化酶
预后
Non-small cell lung cancer
Xanthine oxidoreductase
Prognosis
